ImmuPharma (LON:IMM) Posts Quarterly Earnings Results

ImmuPharma (LON:IMM) released its quarterly earnings results on Tuesday. The company reported GBX (0.84) earnings per share for the quarter, Digital Look Earnings reports. ImmuPharma had a negative return on equity of 353.21% and a net margin of 3,519.56%.

ImmuPharma Price Performance

IMM opened at GBX 3.36 on Tuesday. ImmuPharma has a 12-month low of GBX 3.02 and a 12-month high of GBX 18.90. The stock has a market capitalization of £20.96 million, a PE ratio of -9.08 and a beta of 3.01. The firm’s fifty day moving average price is GBX 3.89 and its 200 day moving average price is GBX 4.53.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.